Christoph Franz, Roche chairman

Roche chair­man Christoph Franz of­fers glint of hope af­ter tiragolum­ab fail — re­port

On the heels of a bad week for Roche and its TIG­IT tiragolum­ab, board chair Christoph Franz is try­ing to look on the bright side.

In an in­ter­view with Reuters, Franz said the com­pa­ny has enough com­ing down the pipeline to make up for tiragolum­ab’s sec­ond straight Phase III flop.

Roche re­vealed on Wednes­day that the drug flunked on a co-pri­ma­ry pro­gres­sion-free sur­vival end­point in com­bi­na­tion with Tecen­triq in a study for PD-L1 high non-small cell lung can­cer pa­tients — send­ing $RHH­BY stock plum­met­ing more than 8%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.